{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:46:44Z","timestamp":1788788804117,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.clml.2013.12.001","type":"journal-article","created":{"date-parts":[[2013,12,16]],"date-time":"2013-12-16T20:19:12Z","timestamp":1387225152000},"page":"231-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Phase I and Extension Study of Clofarabine Plus\u00a0Cyclophosphamide in Patients With\u00a0Relapsed\/Refractory Acute Lymphoblastic\u00a0Leukemia"],"prefix":"10.1016","volume":"14","author":[{"given":"Stefan","family":"Faderl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumudha","family":"Balakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Feliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Plunkett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.12.001_bib1","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","article-title":"Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy","volume":"86","author":"Thomas","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.12.001_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1586\/ehm.09.70","article-title":"Clofarabine in leukemia","volume":"3","author":"Ghanem","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2013.12.001_bib3","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"24","author":"Jeha","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.001_bib4","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","article-title":"Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia","volume":"102","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.001_bib5","first-page":"3580","article-title":"DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.12.001_bib6","first-page":"3030","article-title":"Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine","volume":"56","author":"Xie","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2013.12.001_bib7","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2007-03-081364","article-title":"A\u00a0phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias","volume":"110","author":"Karp","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.001_bib8","first-page":"6335","article-title":"Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias","volume":"9","author":"Gandhi","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.12.001_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2307\/2531628","article-title":"Continual reassessment method: a practical design for phase 1 clinical trials in cancer","volume":"46","author":"O'Quigley","year":"1990","journal-title":"Biometrics"},{"key":"10.1016\/j.clml.2013.12.001_bib10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0197-2456(94)90004-3","article-title":"A\u00a0Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials","volume":"15","author":"Thall","year":"1994","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clml.2013.12.001_bib11","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nsmb.2007","article-title":"Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization","volume":"18","author":"Fairman","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.clml.2013.12.001_bib12","first-page":"2386","article-title":"Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate","volume":"51","author":"Parker","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2013.12.001_bib13","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1182\/blood-2006-05-023259","article-title":"Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal","volume":"108","author":"Moufarij","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.001_bib14","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1016\/S0021-9258(19)50537-3","article-title":"Alterations in the activity and regulation of mammalian ribonucleotide reductase by chlorambucil, a DNA damaging agent","volume":"267","author":"Hurta","year":"1992","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2013.12.001_bib15","article-title":"DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells","author":"Sandoval","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.12.001_bib16","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1182\/blood-2011-08-374710","article-title":"Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"118","author":"Hijiya","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.001_bib17","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2586.2586","article-title":"Clofarabine combinations in adults with refractory\/relapsed acute lymphoblastic leukemia (ALL): a GRAALL report","volume":"118","author":"Pigneux","year":"2011","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501300503X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501300503X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:18Z","timestamp":1761870318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501300503X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S215226501300503X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.12.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I and Extension Study of Clofarabine Plus\u00a0Cyclophosphamide in Patients With\u00a0Relapsed\/Refractory Acute Lymphoblastic\u00a0Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2013.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}